Anaplastic lymphoma kinase inhibitors and their effect on the kidney.

Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non-small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase () gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4. inhibitors are the mainstay treatment for patients with NSCLC harboring a rearrangement of the gene or the oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update. Several ALK-1 inhibitors are used in clinical practice, including crizotinib, ceritinib and alectinib. According to the package insert and published literature, treatment with several ALK-1 inhibitors appears to be associated with the development of peripheral edema and rare electrolyte disorders, kidney failure, proteinuria and an increased risk for the development and progression of renal cysts. This review introduces the different types of ALK inhibitors, focusing on their detailed kidney-related side effects in clinical practice.